2019 American Society of Clinical Oncology Annual Meeting*

Download All
May 31 - June 4, 2019; Chicago, Illinois
Review slidesets and analyses of key data from the 2019 Oncology meeting.

Breast Cancer

Capsule Summary Slidesets

Extended adjuvant endocrine therapy with an additional 5 years of letrozole after tamoxifen prolonged DFS compared with standard-duration sequential endocrine therapy with letrozole in patients with HR-positive early breast cancer.

Released: June 5, 2019

Margetuximab + CT resulted in improved PFS and ORR vs trastuzumab + CT in patients with HER2+ MBC after ≥ 2 previous lines of anti-HER2 therapy.

Released: June 6, 2019

Neratinib + capecitabine significantly prolonged PFS vs lapatinib + capecitabine (HR: 0.76) in patients with HER2+ MBC previously treated with at least 2 lines of therapy.

Released: June 7, 2019

In patients with advanced PD-L1–positive TNBC, first-line atezolizumab + nab-paclitaxel was associated with a 7 month OS benefit compared with placebo + nab-paclitaxel.

Released: June 6, 2019

Palbociclib in combination with endocrine therapy and OFS prolonged PFS vs single-agent capecitabine in premenopausal women with HR+/HER2- MBC.

Released: June 7, 2019

The combination of ribociclib + initial endocrine therapy significantly prolonged median OS vs placebo + endocrine therapy in pre/perimenopausal women with HR+/HER2- advanced breast cancer.

Released: June 11, 2019
Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation
Novartis Pharmaceuticals Corporation
Puma Biotechnology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.